

IN THE CLAIMS:

Please, replace the pending claim set with the following amended claims.


1. (Withdrawn) An isolated polynucleotide molecule encoding a heavy chain variable domain of antibody B2G4, said polynucleotide molecule comprising nucleotides 1 to 378 of SEQ ID NO:8.
2. (Withdrawn) An isolated polynucleotide molecule encoding a light chain variable domain of antibody B2G4, said polynucleotide molecule comprising nucleotides 1 to 372 of SEQ ID NO:9.
3. (Withdrawn) An isolated polynucleotide molecule encoding an antibody-binding fragment, said antibody-binding fragment comprising at least one heavy chain variable domain encoded by the polynucleotide set forth in SEQ ID NO:8 and at least one light chain variable domain encoded by the polynucleotide set forth in SEQ ID NO:9.
4. (Withdrawn) The isolated polynucleotide molecule according to claim 3, wherein said antibody-binding fragment is an scFV fragment.
5. (Withdrawn) The isolated polynucleotide molecule according to claim 3, wherein said antibody-binding fragment is a diabody.
6. (Withdrawn) The isolated polynucleotide molecule according to claim 3, wherein the antibody-binding fragment is a triabody.
7. (Currently amended) ~~The~~ An isolated antibody or antibody-binding fragment, wherein said isolated antibody or antibody-binding fragment comprises a heavy chain comprises an comprising the amino acid sequence ~~having at least 95%~~

- ~~sequence identity to an amino acid sequence~~ encoded by nucleotides 1 to 378 of SEQ ID NO: 8, and wherein said isolated antibody or antibody-binding fragment specifically binds the peptide of SEQ ID NO: 4.
8. (Canceled)
 9. (Currently amended) ~~The~~ An isolated antibody or antibody fragment, wherein said isolated antibody or antibody-binding fragment comprises a light chain ~~comprises an comprising the~~ amino acid sequence ~~having at least 95% sequence identity to an amino acid sequence~~ encoded by nucleotides 1 to 372 of SEQ ID NO: 9, and wherein said isolated antibody or antibody-binding fragment specifically binds the peptide of SEQ ID NO: 4.
 10. (Canceled)
 11. (Currently amended) An isolated antibody or antibody-binding fragment ~~comprising~~, wherein said isolated antibody or antibody-binding fragment comprises at least one heavy and at least one light chain, and wherein said heavy chain comprises ~~an~~ the amino acid sequence ~~having at least 95% sequence identity to an amino acid sequence~~ encoded by nucleotides 1 to 378 of SEQ ID NO: 8, and wherein said light chain comprises ~~an~~ the amino acid sequence ~~having at least 95% sequence identity to an amino acid sequence~~ encoded by nucleotides 1 to 372 of SEQ ID NO: 9, and wherein said antibody or antibody-binding fragment specifically binds to the peptide of SEQ ID NO: 4.
 12. (Canceled)
 13. (Original) The antibody or antibody-binding fragment according to claim 7, wherein said antibody-binding fragment is an scFV fragment.

14. (Original) The antibody or antibody-binding fragment according to claim 9,
wherein said antibody-binding fragment is an scFV fragment.
15. (Original) The antibody or antibody-binding fragment according to claim 11,
wherein said antibody-binding fragment is an scFV fragment.
16. (Original) The antibody or antibody-binding fragment according to claim 11,
wherein said antibody-binding fragment is a diabody.
17. (Original) The antibody or antibody-binding fragment according to claim 11,
wherein the antibody-binding fragment is a triabody.
18. (Canceled)
19. (Canceled)
20. (Canceled)

10/806,419

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Adonia Papathanassiou', is written over a horizontal line.

Adonia Papathanassiou

[P.O. Box 1001]

[Silver Spring, MD 20910]

[tel.: 202.319.5873]

Date: June 4, 2007